Eli Lilly Corp. Stock
Price
Target price
€844.90
€844.90
0.110%
0.9
0.110%
€887.90
14:21 / Tradegate
WKN: 858560 / Symbol: LLY / Name: Eli Lilly / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Eli Lilly Corp. Stock
Eli Lilly Corp. gained 0.110% compared to yesterday.
The stock is an absolute favorite of our community with 71 Buy predictions and no Sell predictions.
With a target price of 887 € there is a slightly positive potential of 4.98% for Eli Lilly Corp. compared to the current price of 844.9 €.
Our community identified positive and negative aspects for Eli Lilly Corp. stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the Eli Lilly Corp. stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.
Pros and Cons of Eli Lilly Corp. in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Eli Lilly Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Eli Lilly Corp. | 0.110% | -0.036% | 11.478% | 96.462% | 59.848% | 327.992% | 744.338% |
| Pfizer Inc. | 0.040% | -0.823% | -1.949% | -22.902% | -0.747% | -22.649% | -30.223% |
| Elanco Animal Health Inc. | 1.440% | -21.749% | -19.783% | 41.498% | -3.609% | -55.764% | - |
| Biogen Inc. | -1.130% | 2.256% | 2.700% | -18.391% | -9.669% | -27.502% | 1.987% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15
Eli Lilly and Company (LLY) appears to have demonstrated strong financial performance in recent years. As a leading pharmaceutical company, LLY's financial statements show growth in key areas such as total assets, net income, and revenue. However, a thorough analysis is needed to identify the potential upsides and downsides of the company's financial performance. This will allow investors to make more informed decisions about the stability and growth potential of LLY.
*Pros: *
Growing revenue and net income: Over the years, LLY has experienced continued growth in total revenue, from $24.54 billion in 2020 to $28.72 billion in 2022. This growth is a positive indicator of the company's strong performance and financial health. Furthermore, LLY's net income has also increased from $6.19 billion in 2020 to $6.24 billion in 2022, showcasing the company's ability to generate consistent profits.
Comments
Eli Lilly's recent FDA approval for its Alzheimer's drug Kisunla is a game-changer. This landmark approval could pave the way for a new era of Alzheimer's treatment, and Lilly is positioning itself as a leader in this space. As an investor, I'm excited about the possibilities. Kisunla's potential to address the early stages of the disease could be a significant breakthrough, and Lilly's strong pipeline of other promising treatments further bolsters my confidence in the company's future. While the stock is currently trading at a premium, I believe the long-term growth potential justifies the price tag. Lilly's innovative approach, coupled with its robust financial performance, makes it an attractive investment opportunity in my view.
Show more
Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.
Show more
Ratings data for LLY provided by MarketBeat
Eli Lilly has been on a roll lately, and I'm quite bullish on the stock. Their recent FDA approval for their Alzheimer's drug is a game-changer, and their partnership with OpenAI to leverage AI in healthcare is incredibly exciting. The company's revenue has been climbing, thanks in part to the strong demand for their weight loss drugs. While the stock did dip a bit in the latest trading session, I think this is a temporary blip and the long-term outlook is very promising. Lilly is making smart moves to stay ahead of the curve, and I believe their innovative approach will continue to pay off for investors. At the current price, I believe the stock is still undervalued and has plenty of room to grow. It's an enticing opportunity, and I'm tempted to add more Lilly to my portfolio.
Show more
